Magnetic nanoparticles and their applications in medicine

Bibliography

• 1  Häfeli U: The history of magnetism in medicine. In: Magnetism in Medicine. Andrä W, Nowak H (Eds). Wiley-VCH, Berlin, Germany, 15–34 (1998).
  Google Scholar
• 2  Bailey RE, Smith AM, Nie S: Quantum dots in biology and medicine. Physica E25,1–12 (2004).
  CASGoogle Scholar
• 3  West JL, Halas NJ: Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Annu. Rev. Biomed. Eng.5,285–292 (2003).
  Medline CASGoogle Scholar
• 4  Moghimi SM, Szebeni J: Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res.42(6),463–478 (2003).
  Medline CASGoogle Scholar
• 5  Monfardini C, Veroneses FM: Stabilization of substances in circulation. Bioconjug. Chem.9(4),418–450 (1998).
  Medline CASGoogle Scholar
• 6  Mornet S, Vasseur S, Grasset F et al.: Magnetic nanoparticle design for medical diagnosis and therapy. J. Mater. Chem.14,2161–2175 (2004).
  CASGoogle Scholar
• 7  Sonvico F, Dubernet C, Colombo P et al.: Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr. Pharm. Des.11,2091–2105 (2005).
  CASGoogle Scholar
• 8  Berry CC, Curtis ASG: Functionalisation of magnetic nanoparticles for applications in biomedicine. J. Phys. D Appl. Phys.36,R198–R206 (2003).
  CASGoogle Scholar
• 9  Bahadur D, Giri J: Biomaterials and magnetism. Sadhana28(3–4),639–656 (2003).
  CASGoogle Scholar
• 10  Ito A, Shinkai M, Honda H et al.: Medical application of functionalized magnetic nanoparticles. J. Biosci. Bioeng.100(1),1–11 (2005).
  Medline CASGoogle Scholar
• 11  Tartaj P, del Puerto Morales M, Veintemillas-Verdaguer S et al.: The preparation of magnetic nanoparticles for applications in biomedicine. J. Phys. D Appl. Phys.36(13),R182–R197 (2003).
  CASGoogle Scholar
• 12  Gupta AK, Gupta MP: Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials26,3995–4021 (2005).
  Medline CASGoogle Scholar
• 13  Pankhurst QA, Connolly J, Jones SK et al.: Applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys.36,R167–R181 (2003).
  CASGoogle Scholar
• 14  Berkov D: Basic physical principles. In: Magnetism in Medicine. Andrä W, Nowak H (Eds). Wiley-VCH, Berlin, Germany, 35–73 (1998).
  Google Scholar
• 15  Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev.53(2),283–318 (2001).
  Medline CASGoogle Scholar
• 16  Hume DA, Ross IL, Himes SR et al.: The mononuclear phagocyte system revisited. J. Leukoc. Biol.72,621–627 (2002).
  Medline CASGoogle Scholar
• 17  Chiannilkulchai N, Driouich Z, Benoit JP et al.: Doxorubucin loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther.5,1–11 (1990).
  Google Scholar
• 18  Pinto-Alphandary H, Andremont A, Couvreur P: Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Anitmicrob. Agents13,155–168 (2000).
  Medline CASGoogle Scholar
• 19  Choi SW, Kim WS, Kim JH: Surface modification of functional nanoparticles for controlled drug delivery. J. Dispersion Sci. Technol.24(3–4),475–487 (2003).
  CASGoogle Scholar
• 20  Zalipsky S: Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug. Chem.6(2),150–165 (1995).
  Medline CASGoogle Scholar
• 21  Peracchia MT: Stealth nanoparticles for intravenous administration. STP Pharma. Sci.13(3),155–161 (2003).
  CASGoogle Scholar
• 22  Weissleder R, Bogdanov A, Neuwelt EA et al.: Long-circulating iron oxides for MR imaging. Adv. Drug Deliv. Rev.16(2–3),321–334 (1995).
  CASGoogle Scholar
• 23  Sudimack J, Lee RJ: Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev.41,147–162 (2000).
  Medline CASGoogle Scholar
• 24  Bonnemain B: Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications a review. J. Drug Target.6(3),167–174 (1998).
  Medline CASGoogle Scholar
• 25  Bjornerud A, Johansson L: The utility of superparamagnetic contrast agents in MRI: theoretical consideration and applications in the cardiovascular system. NMR Biomed.17,465–477 (2004).
  MedlineGoogle Scholar
• 26  Okuhata Y: Delivery of diagnostic agents for magnetic resonance imaging. Adv. Drug Deliv. Rev.37,121–137 (1999).
  Medline CASGoogle Scholar
• 27  Jung CW: Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging13(5),675–691 (1995).
  Medline CASGoogle Scholar
• 28  Högemann D, Josephson L, Weissleder R et al.: Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug. Chem.11(6),941–946 (2000).
  Medline CASGoogle Scholar
• 29  Lesniak C, Schiestel T, Nass R et al.: Synthesis and surface modification of deagglomerated superparamagnetic nanoparticles. Mater. Res. Soc. Symp. Proc.432,169–174 (1997).
  CASGoogle Scholar
• 30  Mornet S, Portier J, Duguet E: A method for synthesis and functionalization of ultrasmall superparamagnetic covalent carriers based on maghemite and dextran. J. Magn. Magn. Mater.293,127–134 (2005).
  CASGoogle Scholar
• 31  Weissleder R, Stark DD, Engelstad BL et al.: Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am. J. Roentgenol.152,167–173 (1989).
  Medline CASGoogle Scholar
• 32  Papisov MI, Bogdanov A, Schaffer B et al.: Colloidal magnetic resonance contrast agents: effect of particule surface on biodistribution. J. Magn. Magn. Mater.122,383–386 (1993).
  CASGoogle Scholar
• 33  Weissleder R, Elizondo G, Wittenberg J et al.: Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology175,489–493 (1990).
  Medline CASGoogle Scholar
• 34  Brusentsov NA, Gogosov VV, Brusentsova TN et al.: Evaluation of ferromagnetic fluids and suspensions for the site-specific radiofrequency-induced hyperthermia of MX11 sarcoma cells in vitro. J. Magn. Magn. Mater.225,113–117 (2001).
  CASGoogle Scholar
• 35  Wada S, Yue L, Tazawa K et al.: New local hyperthermia using dextran magnetite complex (DM) for oral cavity: experimental study in normal hamster tongue. Oral Dis.7,192–195 (2001).
  Medline CASGoogle Scholar
• 36  Weinmann HJ, Ebert W, Misselwitz B et al.: Tissue-specific MR contrast agents. Eur. J. Radiol.46,33–44 (2003).
  MedlineGoogle Scholar
• 37  Reimer P, Balzer T: Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur. Radiol.13,1266–1276 (2003).
  MedlineGoogle Scholar
• 38  Jung CW, Jacobs P: Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging13(5),661–674 (1995).
  Medline CASGoogle Scholar
• 39  Weissleder R, Heautot JF, Schaffer BK et al.: MR lymphography: study of high-efficiency lymphotropic agent. Radiology191,225–230 (1994).
  Medline CASGoogle Scholar
• 40  Guimaraes R, Clement O, Bittoun J et al.: MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR Am. J. Roentgenol.162,201–207 (1994).
  Medline CASGoogle Scholar
• 41  Bellin MF, Lebleu L, Meric JB: Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom. Imaging28(2),155–163 (2003).
  Medline CASGoogle Scholar
• 42  Kellar KE, Fujii DK, Gunther WHH et al.: “NC 100150”, a preparation of iron oxide nanoparticles ideal for positive-contrast MR angiography. Magn. Reson. Mater. Phys. Biol. Med.8(3),207–213 (1999).
  CASGoogle Scholar
• 43  Bulte JWM, Kraitchman DL: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed.17,484–499 (2004).
  Medline CASGoogle Scholar
• 44  Weissleder R, Lee AS, Fischman AJ et al.: Polyclonal human immunoglobin G labeled with polymeric iron oxide: antibody MR imaging. Radiology181(1),245–249 (1991).
  Medline CASGoogle Scholar
• 45  Tiefenauer LX, Kühne G, Andres RY: Antibody-magnetite nanoparticles: in vitro characterization of a potential tumor-specific contrast agent for magnetic resonance imaging. Bioconjug. Chem.4,347–352 (1993).
  Medline CASGoogle Scholar
• 46  Suzuki M, Honda H, Kobayashi T et al.: Development of a target-directed magnetic resonance contrast agent using monoclonal antibody-conjugated magnetic particles. Brain Tumor Pathol.13,127–132 (1996).
  CASGoogle Scholar
• 47  Remsen LG, McCormick CI, Roman-Goldstein S et al.: MR of carcinoma-spectific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles : the potential for non invasive diagnostic. Am. J. Neuroradiol.17(3),411–418 (1996).
  Medline CASGoogle Scholar
• 48  Suwa T, Ozawa S, Ueda M et al.: Magnetic resonance imaging of oesophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int. J. Cancer75,626–634 (1998).
  Medline CASGoogle Scholar
• 49  Zhang Y, Kohler N, Zhang M: Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials23,1553–1561 (2002).
  Medline CASGoogle Scholar
• 50  Kohler N, Fryxell GE, Zhang M: A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J. Am. Chem. Soc.126(23),7206–7211 (2004).
  Medline CASGoogle Scholar
• 51  Choi HC, Choi SR, Zhou R et al.: Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-target delivery. Acad. Radiol.11,996–1004 (2004).
  MedlineGoogle Scholar
• 52  Sonvico F, Mornet S, Vasseur S et al.: Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physico-chemical characterisation and in vitro experiments. Bioconjug. Chem.16,1181–1188 (2005).
  Medline CASGoogle Scholar
• 53  Högemann-Savellano D, Bos E, Blondet C et al.: The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia5(6),495–506 (2003).
  MedlineGoogle Scholar
• 54  Högemann D, Ntziachristos V, Josephson L et al.: High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug. Chem.13,116–121 (2002).
  MedlineGoogle Scholar
• 55  Nielsen OS, Horsman M, Overgaard J: A future for hyperthermia in cancer treatment? Eur. J. Cancer37,1587–1589 (2001).
  Medline CASGoogle Scholar
• 56  Overgaard K, Overgaard J: Investigations on the possibility of a thermic tumour therapy – I. Eur. J. Cancer8,65–78 (1972).
  Medline CASGoogle Scholar
• 57  Moroz P, Jones SK, Gray BN: Status of hyperthermia in the treatment of advanced liver cancer. J. Surg. Oncol.77,259–269 (2001).
  Medline CASGoogle Scholar
• 58  Jordan A, Scholz R, Wust P et al.: Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic induced excitation of biocompatible superparamagnetic nanoparticles. J. Magn. Magn. Mater.201,413–419 (1999).
  CASGoogle Scholar
• 59  Overgaard J: The current and potential role of hyperthermia in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.16(3),535–549 (1989).
  Medline CASGoogle Scholar
• 60  Dubois JB: Hyperthermie: principes, techniques. Place actuelle dans le traitement des cancers. Bull. Cancer Radiother.82,207–224 (1995).
  Medline CASGoogle Scholar
• 61  Owens SD, Gasper PW: Hyperthermic therapy for HIV infection. Med. Hypotheses44,235–242 (1995).
  Medline CASGoogle Scholar
• 62  Gel'vich EA, Mazokhin VN: Technical aspects of electromagnetic hyperthermia in medicine. Crit. Rev. Biomed. Eng.29(1),77–97 (2001).
  MedlineGoogle Scholar
• 63  Moroz P, Jones SK, Gray BN: Magnetically mediated hyperthermia: current status and future directions. Int. J. Hyperthermia18(4),267–284 (2002).
  Medline CASGoogle Scholar
• 64  Andrä W: Magnetic hyperthermia. In: Magnetism in Medicine. Andrä W, Nowak H (Eds). Wiley-VCH, Berlin, Germany, 455–470 (1998).
  Google Scholar
• 65  Hill DA: Further studies of human whole-body radiofrequency absorption rates. Bioelectromagnetics6(1),33–40 (1985).
  Medline CASGoogle Scholar
• 66  Le B, Shinkai M, Kitade T et al.: Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J. Chem. Eng. Jpn34(1),66–72 (2001).
  CASGoogle Scholar
• 67  Gneveckow U, Jordan A, Scholz R et al.: Description and characterization of the novel hyperthermia- and thermoablation-system MFH (R) 300F for clinical magnetic fluid hyperthermia. Med. Phys.31(6),1444–1451 (2004).
  MedlineGoogle Scholar
• 68  Jordan A, Wust P, Scholz R et al.: Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int. J. Hyperthermia12(6),705–722 (1996).
  Medline CASGoogle Scholar
• 69  Jordan A, Scholz R, Wust P et al.: Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. J. Magn. Magn. Mater.194,185–196 (1999).
  CASGoogle Scholar
• 70  Jordan A, Scholz R, Wust P et al.: Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int. J. Hyperthermia13(6),587–605 (1997).
  Medline CASGoogle Scholar
• 71  Johannsen M, Jordan A, Scholz R et al.: Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. J. Endurolog.18(5),495–500 (2004).
  MedlineGoogle Scholar
• 72  Johannsen M, Gneveckow U, Eckelt L et al.: Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int. J. Hyperthermia21(7),637–647 (2005).
  Medline CASGoogle Scholar
• 73  Kawai N, Ito A, Nakahara Y et al.: Anticancer effect of hyperthermia on prostate cancer mediated by magnetite cationic liposomes and immune-response induction in transplanted syngeneic rats. Prostate64,373–381 (2005)
  Medline CASGoogle Scholar
• 74  Tanaka K, Ito A, Kobayashi T et al.: Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int. J. Cancer116,624–633 (2005).
  Medline CASGoogle Scholar
• 75  Kawai N, Ito A, Nakahara Y et al.: Complete regression of esperimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core. Prostate66,718–727 (2006).
  Medline CASGoogle Scholar
• 76  Suzuki M, Shinkai M, Kamihira M et al.: Preparation and characteristics of magnetite-labelled antibody with the use of poly(ethylene glycol) derivatives. Biotechnol. Appl. Biochem.21,335–345 (1995).
  Medline CASGoogle Scholar
• 77  DeNardo SJ, DeNardo GL, Miers LA et al.: Development of tumor targeting bioprobes (¹¹¹In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin. Cancer Res.11,7087s–7092s (2005).
  Medline CASGoogle Scholar
• 78  Quesson B, Vimeux F, Salomir R et al.: Automatic control of hyperthermic therapy based on real-time fourier analysis of MR temperature maps. Magn. Reson. Med.47(6),1065–1072 (2002).
  MedlineGoogle Scholar
• 79  Deger S, Taymoorian K, Boehmer D et al.: Thermoradiotherapy using interstitial self-regulating thermoseeds: an intermediate analysis of a phase II trial. Eur. Urol.45(5),574–579 (2004).
  MedlineGoogle Scholar
• 80  Kuznetsov AA, Shlyakhtin OA, Brusentsov NA et al.: “Smart” mediators for self-controlled inductive heating. Eur. Cell. Mater.3(Suppl. 2),75–77 (2002).
  Google Scholar
• 81  Vasseur S, Duguet E, Portier J et al.: Lanthanum manganese perovskite nanoparticles as possible in vivo mediators for magnetic hyperthermia. J. Magn. Magn. Mater.302,315–320 (2006).
  CASGoogle Scholar
• 82  Rabin Y: Is intracellular hyperthermia superior to extracellular hyperthermia in the thermal sense? Int. J. Hyperthermia18(3),194–202 (2002).
  Medline CASGoogle Scholar
• 83  Lübbe AS, Alexiou C, Bergemann C: Clinical applications of magnetic drug targeting. J. Surg. Res.95,200–206 (2001).
  Medline CASGoogle Scholar
• 84  Edelman ER, Kost J, Bobeck T et al.: Regulation of drug release from polymer matrices by oscillating magnetic fields. J. Biomed. Mater. Res.19,67–83 (1985).
  Medline CASGoogle Scholar
• 85  Sershen SR, Westcott SL, Halas NJ et al.: Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J. Biomed. Mater. Res.51,293–298 (2000).
  Medline CASGoogle Scholar
• 86  Kreuter J: Nanoparticutate systems for brain delivery drugs. Adv. Drug Deliv. Rev.47,65–81 (2001).
  Medline CASGoogle Scholar
• 87  Lockman PR, Mumper RJ, Khan MA et al.: Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev. Ind. Pharm.28(1),1–12 (2002).
  Medline CASGoogle Scholar
• 88  Couvreur P, Brigger I, Dubernet C: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev.54(5),631–651 (2002).
  MedlineGoogle Scholar
• 89  Kumar MNV: Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci.3(2),234–258 (2000).
  MedlineGoogle Scholar
• 90  Ghosh PK: Hydrophilic polymeric nanoparticles as drug carriers. Indian J. Biochem. Biophys.37,273–282 (2000).
  CASGoogle Scholar
• 91  Mordon S, Desmettre T, Devoisselle JM et al.: Selective laser photocoagulation of blood vessels in a hamster skin flap model using a specific ICG formulation. Laser Surg. Med.21(4),365–373 (1997).
  Medline CASGoogle Scholar
• 92  Wallis F, Gilbert FJ: Magnetic resonance imaging in oncology: an overview. JR Coll. Surg. Edinb.44,117–125 (1999).
  Medline CASGoogle Scholar
• 93  Harisinghani MG, Barentsz J, Hahn PF et al.: Non invasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med.348,2491–2499 (2003).
  MedlineGoogle Scholar
• 101  MagForce Nanotechnologies AG www.magforce.de/en/
  Google Scholar
• 201  CANADIAN PATENTS AND DEVELOPMENT LIMITED.: US4452773 (1984).
  Google Scholar
• 202  ADVANCED MAGNETICS, INC.: US5248492 (1993).
  Google Scholar
• 203  INSTITUT FUR NEUE MATERIALIEN GEM. GmbH: US6541039 (2003).
  Google Scholar